Methods of Preventing or Treating Respiratory Conditions

Abstract

The present invention provides prophylactic an therapeutic protocols designed to prevent, manage, treat, or ameliorate a respiratory condition or one or more symptoms thereof. In particular, the present invention provides methods for preventing, managing, treating, or ameliorating a respiratory condition or one or symptoms caused by environmental factors or a respiratory infection. The present invention encompasses combination therapies, pharmaceutical compositions, articles of manufacture, and kits.

1 - 26 . (canceled) 
     
     
         27 . A method of treating or ameliorating a respiratory infection, or a symptom thereof, in a human subject suffering therefrom, said method comprising administering to said human subject an effective amount of an antibody or fragment thereof that immunospecifically binds IL-9, wherein the antibody or fragment thereof is selected from the group consisting of 4D4, 4D4 H2-1 D11, 4D4com-XF-9, 4D4com-2F9, 71A10, 7F3, 7F3 22D3, 7F3com, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         28 . The method of  claim 27  further comprising administering an effective amount of at least one other therapy that is not administration of an IL-9 antagonist. 
     
     
         29 . The method of  claim 28 , wherein the therapy is an immunomodulatory agent, an anti-inflammatory agent, an anti-viral agent, an antibiotic, an antifungal agent or a mast cell modulator. 
     
     
         30 . The method of  claim 27 , wherein the subject is a pre-term infant, an infant, a child or an elderly person. 
     
     
         31 . The method of  claim 27 , wherein the subject has bronchopulmonary dysplasia, congenital heart disease, cystic fibrosis or acquired or congenital immunodeficiency. 
     
     
         32 . The method of  claim 27 , wherein the respiratory infection is a viral infection, a bacterial infection or a fungal infection. 
     
     
         33 . A method of preventing the development, onset or progression of one or more asthma-like symptoms or asthma in a human child that previously had a respiratory infection or concurrently has a respiratory infection, said method comprising administering to said human subject an effective amount of an antibody or fragment thereof that immunospecifically binds IL-9, wherein the antibody or fragment thereof is selected from the group consisting of 4D4, 4D4 H2-1 D11, 4D4com-XF-9, 4D4com-2F9, 71A10, 7F3, 7F3 22D3, 7F3com, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         34 . The method of  claim 33  further comprising administering an effective amount of at least one other therapy that is not administration of an IL-9 antagonist. 
     
     
         35 . The method of  claim 34 , wherein the therapy is an immunomodulatory agent, an anti-inflammatory agent, an anti-viral agent, an antibiotic, an antifungal agent or a mast cell modulator. 
     
     
         36 . The method of  claim 33 , wherein the child has bronchopulmonary dysplasia, congenital heart disease, cystic fibrosis or acquired or congenital immunodeficiency. 
     
     
         37 . The method of  claim 33 , wherein the respiratory infection is a viral infection, a bacterial infection or a fungal infection. 
     
     
         38 . A method of treating or ameliorating wheezing in a human subject suffering therefrom, said method comprising administering to said human subject an effective amount of an antibody or fragment thereof that immunospecifically binds IL-9, wherein the antibody or fragment thereof is selected from the group consisting of 4D4, 4D4 H2-1 D11, 4D4com-XF-9, 4D4com-2F9, 71A10, 7F3, 7F3 22D3, 7F3com, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4. 
     
     
         39 . The method of  claim 38  further comprising administering an effective amount of at least one other therapy that is not administration of an IL-9 antagonist. 
     
     
         40 . The method of  claim 39 , wherein the therapy is an immunomodulatory agent, an anti-inflammatory agent, an anti-viral agent, an antibiotic, an antifungal agent or a mast cell modulator. 
     
     
         41 . The method of  claim 38 , wherein the subject is a pre-term infant, an infant, a child or an elderly person. 
     
     
         42 . The method of  claim 38 , wherein the subject has bronchopulmonary dysplasia, congenital heart disease, cystic fibrosis or acquired or congenital immunodeficiency. 
     
     
         43 . A method of treating or ameliorating asthma or an allergy, or one or more symptoms thereof, in a human subject suffering therefrom, said method comprising administering to said human subject:
 an effective amount of an antibody or fragment thereof that immunospecifically binds IL-9, wherein the antibody or fragment thereof is selected from the group consisting of 4D4, 4D4 H2-1 D11, 4D4com-XF-9, 4D4com-2F9, 71A10, 7F3, 7F3 22D3, 7F3com, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4, and   an effective amount of at least one other asthma or allergy therapy.   
     
     
         44 . The method of  claim 43 , wherein the therapy is an immunomodulatory agent, an anti-inflammatory agent, an anti-viral agent, an antibiotic, an antifungal agent or a mast cell modulator. 
     
     
         45 . The method of  claim 43 , wherein the subject is a pre-term infant, an infant, a child or an elderly person. 
     
     
         46 . The method of  claim 43 , wherein the subject has bronchopulmonary dysplasia, congenital heart disease, cystic fibrosis or acquired or congenital immunodeficiency.